Study Details

General Information

Janssen Vaccine VAC31518COV3009

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

ProtocolVAC31518COV3009
IdentifierHorizon
UID1c60fd91-f007-4cbf-bb96-4b0edd3bd323
StatusPI Declined
Phase3
CategoryCOVID-19 / Adult
Launch Year0
NCT Number-
Created2020-10-23 17:48
Last Updated2020-10-23 17:48

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment OpenNo
First Patient First VisitNo
Site Initiation Mtg.No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout DateNo
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalMohseni, RizwanaRMohseniNo
Recruiter-No
Coordinator-No
RegulatoryRamirez, ClaudiaCRamirezNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorJanssen
DivisionJanssen
TeamJanssen
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CRO
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGray
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?